Investors Newsletter_September 2025
September 9, 2025
Investors Newsletter_September 2025
Dear Friends and Investors,
I’m excited to share a brief update on RegenMed’s progress. We’ve had a busy season, advancing partnerships, strengthening our investor position, and extending our reach in both healthcare innovation and academic collaboration. Here are four highlights we’re proud of:
Partnering with OREF to Launch MOTIV™
.png)
Together with the Orthopaedic Research and Education Foundation, we launched MOTIV™, a peer-reviewed library of real-world evidence datasets in musculoskeletal medicine. This is a milestone toward replacing unverifiable “big data” with clinically rigorous, FDA-fit datasets that improve patient outcomes and support value-based care.
Sponsoring UW–Madison’s Capstone Project
.png)
We’re investing in the next generation of innovators by sponsoring a University of Wisconsin Computer Sciences Capstone team. Students will enhance our patient-reported outcomes (ePRO) platform with gamification and UX improvements, mentored by RegenMed leaders. We join sponsors like Epic, Google, and GE HealthCare in supporting this nationally recognized program.
Welcoming HyperFlex Medical as a New Client
.png)
We’re proud to add HyperFlex Medical to our growing client base. Their HyperFlex® Bunion Correction System is a minimally invasive, bone-preserving solution for the 23% of adults affected by bunions. With a market projected to grow from $1.47B in 2023 to $2.33B by 2032, this partnership shows how RegenMed Circles support both innovation and scale in high-demand specialties.
Launching Our New Investor Page
.png)
We’ve launched a dedicated Investor Page, outlining why RegenMed is a Zero-to-One company in a $100B+ healthcare data market. With strong recurring revenues, AI-ready infrastructure, and early investor momentum, we belive we’re building one of the most compelling opportunities in healthcare data today.
We’re grateful for your continued support as we scale RegenMed’s mission to make real-world healthcare data both trustworthy and transformative. Stay tuned for more updates in the months ahead.
Warm regards,
Michael P. Tierney
CEO, RegenMed
Investors Newsletter_September 2025
September 9, 2025
Dear Friends and Investors,
I’m excited to share a brief update on RegenMed’s progress. We’ve had a busy season, advancing partnerships, strengthening our investor position, and extending our reach in both healthcare innovation and academic collaboration. Here are four highlights we’re proud of:
Partnering with OREF to Launch MOTIV™
Together with the Orthopaedic Research and Education Foundation, we launched MOTIV™, a peer-reviewed library of real-world evidence datasets in musculoskeletal medicine. This is a milestone toward replacing unverifiable “big data” with clinically rigorous, FDA-fit datasets that improve patient outcomes and support value-based care.
Sponsoring UW–Madison’s Capstone Project
We’re investing in the next generation of innovators by sponsoring a University of Wisconsin Computer Sciences Capstone team. Students will enhance our patient-reported outcomes (ePRO) platform with gamification and UX improvements, mentored by RegenMed leaders. We join sponsors like Epic, Google, and GE HealthCare in supporting this nationally recognized program.
Welcoming HyperFlex Medical as a New Client
We’re proud to add HyperFlex Medical to our growing client base. Their HyperFlex® Bunion Correction System is a minimally invasive, bone-preserving solution for the 23% of adults affected by bunions. With a market projected to grow from $1.47B in 2023 to $2.33B by 2032, this partnership shows how RegenMed Circles support both innovation and scale in high-demand specialties.
Launching Our New Investor Page
We’ve launched a dedicated Investor Page, outlining why RegenMed is a Zero-to-One company in a $100B+ healthcare data market. With strong recurring revenues, AI-ready infrastructure, and early investor momentum, we belive we’re building one of the most compelling opportunities in healthcare data today.
We’re grateful for your continued support as we scale RegenMed’s mission to make real-world healthcare data both trustworthy and transformative. Stay tuned for more updates in the months ahead.
Warm regards,
Michael P. Tierney
CEO, RegenMed
